Abstract
Normal cells in culture divide a certain amount of times and undergo a process termed replicative senescence. Telomere loss is thought to control entry into senescence. Activation of telomerase in tumors bypasses cellular senescence and is thus a requirement for tumor progression. We reported previously the preferential incorporation of 3′-azido-2′, 3′-dideoxythymidine (AZT) in telomeric sequences of immortalized cells in culture. In this work, we have investigated the effects of chronic in vitro AZT exposure on F3II mouse mammary carcinoma cells. We demonstrate, for the first time, that AZT-treated tumor cells have a reduced tumorigenicity in syngeneic BALB/c mice. Tumor incidence was reduced and survival was prolonged in animals inoculated with AZT-treated cells when comparing with control counterparts. The number and size of spontaneous metastases were also decreased in animals inoculated with AZT-treated cells. In addition, we present evidence of morphological and biochemical signs of senescence, as shown by the staining for senescence associated ß-galactosidase activity, and induction of programmed cell death, as demonstrated by an increase of caspase-3 activity, in tumor cells exposed to AZT. These data indicate that chronic exposure of mammary carcinoma cells to AZT may be sufficient to induce a senescent phenotype and to reduce tumorigenicity.
References
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu C-P, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352, 1998
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2014, 1994
De Lange T: Telomeres and senescence: ending the debate. Science 279: 334-335, 1998
Gomez DE, Kassim A, Olivero OA: Preferential incorporation of 30-azido-2, 30-dideoxythymidine (AZT) in telomeric sequences of CHO cells. Int J Oncol 7: 1057-1060, 1995
Gomez DE, Tejera AM, Olivero OA: Irreversible telomere shortening by 30-azido-2, 30-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun 246: 107-110, 1998
Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC: Transplacental effects of 30-azido-20, 30-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89: 1602-1608, 1997
Diwan BA, Riggs CW, Logdson D, Haines DC, Olivero OA, Rice JM, Yuspa SH, Poirier MC, Anderson LM: Multiorgan transplacental and neonatal carcinogenicity of 30-azido-30-deoxythymidine in mice. Toxicol Appl Pharmacol 161: 82-99, 1999
Falcone A, Lencioni M, Brunetti I, Pfanner E, Allegrini G, Antonuzzo A, Andreuccetti M, Malvaldi G, Danesi R, Del Tacca M, Conte PF: Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudineinduced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol 8: 539-545, 1997
Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, Nethersell AB, Conte PF: Intravenous azidothymidine with fluorouracil and leucovor in: a phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 14: 729-736, 1996
Alonso DF, Farías EF, Urtreger A, Ladeda V, Vidal MC, Bal de Kier Joffé E: Characterization of F3II, a mammary sarcomatoid carcinoma cell line originated from a mouse adenocarcinoma. J Surg Oncol 62: 288-297, 1996
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995
Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93, 1998
Porter AG, Janicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999
Rhyu MS: Telomeres, telomerase, and immortality. J Natl Cancer Inst 87: 884-894, 1995
Strahl C, Blackburn EH: The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 22: 893-900, 1994
Strahl C, Blackburn EH: Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16: 53-65, 1996
Melana SM, Holland JF, Pogo BG-T: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 30-azido-30-deoxythymidine. Clin Cancer Res 4: 693-696, 1998
Yegorov YE, Chernov DN, Akimov SS, Bolsheva NL, Krayevsky AA, Zelen AV: Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett 389: 115-118, 1996
Mark J, Zijlmans JM, Martens UM, Poon SSS, Raap AK, Tanke HJ, Ward RK, Lansdorp PM: Telomeres in the mouse have large inter-chromosomal variations in the number of T2AG3 repeats. Proc Natl Acad Sci USA 94: 7423-7428, 1997
Lee HW, Blasco MA, Gottlieb GJ, Horner JW, Greider CW, DePinho RA: Essential role of mouse telomerase in highly proliferative organs. Nature 392: 569-574, 1998
Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B, Cowell JK, Barna BP: Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 12: 801-811, 1998
Williams SS, Alosco TR, Croy BA, Bankert RB: The study of human neoplastic disease in severe combined immunodeficient mice. Lab Anim Sci 43: 139-146, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tejera, A.M., Alonso, D.F., Gomez, D.E. et al. Chronic In Vitro Exposure to 3′-Azido-2′, 3′-Dideoxythymidine Induces Senescence and Apoptosis and Reduces Tumorigenicity of Metastatic Mouse Mammary Tumor Cells. Breast Cancer Res Treat 65, 93–99 (2001). https://doi.org/10.1023/A:1006477730934
Issue Date:
DOI: https://doi.org/10.1023/A:1006477730934